VivoSeq
Oncology

Hodgkins Lymphoma

73

Pipeline Programs

0

Active Trials

36

Companies Involved

Hodgkins lymphoma is a moderately active landscape with 73 programs across 36 companies. The most active players are SymBio Pharmaceuticals, Gilead, Iovance Biotherapeutics, Inc.. 31 therapies are approved with 4 more in late-stage development.

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

86/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

73%

Small molecule

52 of 71 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody1521%Protein / enzyme34%Antibody–drug conjugate11%

Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 100% of 75 pipeline programs.

Trial Status

7

clinical trials

Completed6 · 86%
Terminated1 · 14%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)